Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sesen Bio Inc (NQ: SESN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Mar 7, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sesen Bio Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Sesen Bio Stockholders Approve Merger with Carisma Therapeutics March 02, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results February 28, 2023 From Sesen Bio, Inc. Via Business Wire Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma February 21, 2023 From Sesen Bio, Inc. Via Business Wire Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting February 16, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger February 16, 2023 From Sesen Bio, Inc. Via Business Wire BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics February 15, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger February 14, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger February 02, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio Receives NASDAQ Delisting Notice January 30, 2023 From Sesen Bio, Inc. Via Business Wire Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders January 26, 2023 From Sesen Bio, Inc. Via Business Wire Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support January 25, 2023 From On behalf of Bradley L. Radoff Via Business Wire Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics January 19, 2023 From Sesen Bio, Inc. Via Business Wire Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger January 05, 2023 From On behalf of Bradley L. Radoff Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sesen Bio, Inc. (Nasdaq - SESN), IsoPlexis (Nasdaq - ISO), Trean Insurance Group, Inc. (Nasdaq - TIG), Brunswick Bancorp (OTC – BRBW) January 04, 2023 From Brodsky & Smith LLC Via GlobeNewswire Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics January 04, 2023 From Sesen Bio, Inc. Via Business Wire Investor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with Carisma January 03, 2023 From On behalf of Bradley L. Radoff Via Business Wire Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger December 29, 2022 From Sesen Bio, Inc. Via Business Wire Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update November 07, 2022 From Sesen Bio Via Business Wire SESEN BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sesen Bio, Inc. - SESN September 21, 2022 From Kahn Swick & Foti, LLC Via Business Wire SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders September 21, 2022 From Halper Sadeh LLC Via Business Wire Sesen Bio and Carisma Therapeutics Announce Merger Agreement September 21, 2022 From Sesen Bio, Inc. Via Business Wire Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update August 08, 2022 From Sesen Bio Via Business Wire Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US July 18, 2022 From Sesen Bio Via Business Wire Sesen Bio Reports First Quarter 2022 Financial Results and Business Update May 09, 2022 From Sesen Bio Via Business Wire Sesen Bio Provides Strategic Update May 03, 2022 From Sesen Bio Via Business Wire Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™ February 28, 2022 From Sesen Bio Via Business Wire Sesen Bio Further Enhances Team with Key Hires January 10, 2022 From Sesen Bio Via Business Wire Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™ December 09, 2021 From Sesen Bio, Inc. Via Business Wire Sesen Bio Strengthens Medical Team November 29, 2021 From Sesen Bio Via Business Wire Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role November 23, 2021 From Sesen Bio Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.